[Inflammatory cytokines, soluble interleukin-6 receptors, and fragmented cytokeratin-18 as indicators of non-alcoholic steatohepatitis].

IF 0.3 4区医学 Q3 MEDICINE, GENERAL & INTERNAL

Terapevticheskii Arkhiv Pub Date : 2025-03-26 DOI:10.26442/00403660.2025.02.203123

A A Shipovskaya, O P Dudanova, I V Kurbatova

{"title":"[Inflammatory cytokines, soluble interleukin-6 receptors, and fragmented cytokeratin-18 as indicators of non-alcoholic steatohepatitis].","authors":"A A Shipovskaya, O P Dudanova, I V Kurbatova","doi":"10.26442/00403660.2025.02.203123","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin (IL)-1β, 8, 6, soluble IL-6 receptors (sIL-6R) and fragmented cytokeratin-18 (FCK-18) as indicators of non-alcoholic steatohepatitis (NASH).Materials and methods: 173 NASH patients aged 47.0±10.8 years were examined: 118 (68.2%) - men, 55 (31.8%) - women. The following markers were determined: TNF-α (Human TNFα Platinum ELISA, eBioscience, Austria), IL-1β, 8, 6 (Vector-Best, Russia), sIL-6R (Human sIL-6R ELISA, eBioscience, Austria), FCK-18 (TPS ELISA, Biotech, Sweden), insulin (Insulin TEST System, USA), HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) and NAFLD fibrosis score (NFS) were calculated.Results: The highest level in NASH patients compared with healthy individuals was observed for IL-6 - 8.4±1.6 pg/ml versus 2.8±0.9 pg/ml (p=0.001), FCK-18 - 295.3±56.3 U/l versus 110.5±30.2 U/l (p=0.0001), then IL-8 - 17.3±6.7 pg/ml vs 7.6±1.9 pg/ml (p=0.003), TNF-α - 6.3±0.4 pg/ml versus 4.1±0.8 pg/ml (p=0.0001), sIL-6R - 151.5±21.2 ng/ml vs 95.9±12.5 ng/ml (p<0.05); IL-1β did not change - 5.3±1.4 pg/ml versus 4.7±1.5 pg/ml (p=0.3) respectively. FCK-18 showed the highest correlations with TNF-α (r=0.73), HOMA-IR (r=0.73), alanine aminotransferase (r=0.71), erythrocyte sedimentation rate (r=0.23), IL-6 (r=0.22); p<0.05. TNF-α correlated with FCK-18 (r=0.73), cholesterol (r=0.61), albumin (r=-0.42), fibrinogen (r=0.21), leukocyte count (r=0.21); p<0.05. IL-8 correlated with triglycerides (r=0.79) and HDL (r=-0.77), IL-6 - with NFS (r=0.63) and FCK-18 (r=0.22), rIL-6R - with aspartate aminotransferase (r=0.62); p<0.05.Conclusion: TNF-α, IL-8, 6, sIL-6R and FCK-18 should be used as non-invasive biomarkers of NASH.","PeriodicalId":22209,"journal":{"name":"Terapevticheskii Arkhiv","volume":"97 2","pages":"115-120"},"PeriodicalIF":0.3000,"publicationDate":"2025-03-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Terapevticheskii Arkhiv","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.26442/00403660.2025.02.203123","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate inflammatory cytokines, such as tumor necrosis factor α (TNF-α), interleukin (IL)-1β, 8, 6, soluble IL-6 receptors (sIL-6R) and fragmented cytokeratin-18 (FCK-18) as indicators of non-alcoholic steatohepatitis (NASH).

Materials and methods: 173 NASH patients aged 47.0±10.8 years were examined: 118 (68.2%) - men, 55 (31.8%) - women. The following markers were determined: TNF-α (Human TNFα Platinum ELISA, eBioscience, Austria), IL-1β, 8, 6 (Vector-Best, Russia), sIL-6R (Human sIL-6R ELISA, eBioscience, Austria), FCK-18 (TPS ELISA, Biotech, Sweden), insulin (Insulin TEST System, USA), HOMA-IR (Homeostasis Model Assessment of Insulin Resistance) and NAFLD fibrosis score (NFS) were calculated.

Results: The highest level in NASH patients compared with healthy individuals was observed for IL-6 - 8.4±1.6 pg/ml versus 2.8±0.9 pg/ml (p=0.001), FCK-18 - 295.3±56.3 U/l versus 110.5±30.2 U/l (p=0.0001), then IL-8 - 17.3±6.7 pg/ml vs 7.6±1.9 pg/ml (p=0.003), TNF-α - 6.3±0.4 pg/ml versus 4.1±0.8 pg/ml (p=0.0001), sIL-6R - 151.5±21.2 ng/ml vs 95.9±12.5 ng/ml (p<0.05); IL-1β did not change - 5.3±1.4 pg/ml versus 4.7±1.5 pg/ml (p=0.3) respectively. FCK-18 showed the highest correlations with TNF-α (r=0.73), HOMA-IR (r=0.73), alanine aminotransferase (r=0.71), erythrocyte sedimentation rate (r=0.23), IL-6 (r=0.22); p<0.05. TNF-α correlated with FCK-18 (r=0.73), cholesterol (r=0.61), albumin (r=-0.42), fibrinogen (r=0.21), leukocyte count (r=0.21); p<0.05. IL-8 correlated with triglycerides (r=0.79) and HDL (r=-0.77), IL-6 - with NFS (r=0.63) and FCK-18 (r=0.22), rIL-6R - with aspartate aminotransferase (r=0.62); p<0.05.

Conclusion: TNF-α, IL-8, 6, sIL-6R and FCK-18 should be used as non-invasive biomarkers of NASH.

查看原文本刊更多论文

[炎性细胞因子、可溶性白细胞介素-6受体和碎片化细胞角蛋白-18作为非酒精性脂肪性肝炎的指标]。

目的：探讨肿瘤坏死因子α (TNF-α)、白细胞介素(IL)-1β、8,6、可溶性IL-6受体（sIL-6R）和碎片化细胞角蛋白-18 （FCK-18）等炎性因子作为非酒精性脂肪性肝炎（NASH）的指标。材料和方法：173例年龄47.0±10.8岁的NASH患者：男性118例（68.2%），女性55例（31.8%）。测定以下标志物：TNF-α （Human TNF-α Platinum ELISA, eBioscience，奥地利）、IL-1β, 8,6 （Vector-Best，俄罗斯）、sIL-6R （Human sIL-6R ELISA, eBioscience，奥地利）、fsk -18 （TPS ELISA, Biotech，瑞典）、胰岛素（insulin TEST System，美国）、HOMA-IR（胰岛素抵抗稳态模型评估）和NAFLD纤维化评分（NFS）。结果：与健康人群相比，NASH患者IL-6水平最高，分别为8.4±1.6 pg/ml和2.8±0.9 pg/ml (p=0.001)， FCK-18为295.3±56.3 U/l和110.5±30.2 U/l (p=0.0001)， IL-8为17.3±6.7 pg/ml和7.6±1.9 pg/ml (p=0.003)， TNF-α为6.3±0.4 pg/ml和4.1±0.8 pg/ml (p=0.0001)， sIL-6R为151.5±21.2 ng/ml和95.9±12.5 ng/ml （pp=0.3）。FCK-18与TNF-α (r=0.73)、HOMA-IR （r=0.73）、丙氨酸转氨酶（r=0.71）、红细胞沉降率（r=0.23）、IL-6 （r=0.22）相关性最高；p0.05。TNF-α与FCK-18 （r=0.73）、胆固醇（r=0.61）、白蛋白（r=-0.42）、纤维蛋白原（r=0.21）、白细胞计数（r=0.21）相关；p0.05。IL-8与甘油三酯（r=0.79）和HDL （r=-0.77）相关，IL-6 -与NFS （r=0.63）和FCK-18 （r=0.22）相关，il - 6r -与天冬氨酸转氨酶（r=0.62）相关；p0.05。结论：TNF-α、il - 8,6、sIL-6R和FCK-18可作为NASH的无创生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Terapevticheskii Arkhiv 医学-医学：内科

CiteScore

1.40

自引率

33.30%

发文量

171

审稿时长

3-8 weeks

期刊介绍： Терапевтический архив The journal was founded by the prominent Russian therapists M.P. Konchalovsky and G.F. Lang in 1923. Then its editors-in-chief were Professors V.N. Vinogradov and A.G. Gukasyan. Since 1972, E.I. Chazov, Academician of the Russian Academy of Sciences, has been heading the editorial board of the journal. Over 90 years, there have been more than 1000 issues where the authors and editorial staff have done their best for readers to keep abreast of current advances in medical science and practice and for physicians to master the advanced principles of recognition and treatment of a wide spectrum of visceral diseases. The papers published in the journal (editorials, original articles, lectures, reviews, etc.) cover both current scientific achievements and practical experience in diagnosing, treating, and preventing visceral diseases. The authors of publications are not only Russian, but also foreign scientists and physicians. All papers are peer-reviewed by highly qualified Russian specialists. The journal is published monthly. Traditionally, each issue has predominantly certain thematic areas covering individual therapy specializations. Every year, one of the issues is devoted to related problems in practical medicine (allergology and immunology, neurology and psychiatry, obstetrics, oncology, etc.). This all draws the attention of the reading public to the journal. The journal is indexed in RSCI (Russian Science Citation Index), PubMed/Medline, Index Medicus, Scopus/EMBASE, Web of Science Core Collection (Science Citation Index Expanded), Web of Science (Russian Science Citation Index - RSCI, Current Contents Connect, BIOSIS Previews), Google Scholar, Ulrich''s Periodicals Directory. The journal is included in the list of periodicals recommended by the Higher Attestation Committee for publishing the papers containing the basic materials of doctoral and candidate dissertations. By the decision of the Presidium of the Russian Academy of Medical Sciences, the “Therapevticheskiy Arkhiv” was awarded the Botkin medal. It was admitted to the European Association of Sciences Editors (EASE). The journal was honored with the Golden Press Fund decoration at the 13th International Press Professional Exhibition.